Oct 14 2009
Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has conducted further evaluation of the patent infringement lawsuit filed against the company last week by Cook Medical, and of the patents asserted in the lawsuit. Based upon this evaluation, Endologix believes that the alleged infringement is without merit and the company intends to vigorously defend its position.
John McDermott, Endologix President and Chief Executive Officer, said, "We are pleased that our initial evaluation of these claims, which Cook Medical waited for years to assert, has already yielded support for numerous promising defenses."
SOURCE Endologix, Inc.